Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Obscurin-PH is a therapeutic protein domain derived from the giant cytoskeletal protein obscurin, which is normally expressed in breast epithelium but often lost in breast cancer. It acts as a non-chemical inhibitor of the PI3K/AKT signaling pathway by specifically binding and sequestering the p85 regulatory subunit of Phosphoinositide 3-kinase (PI3K). By preventing the assembly and activation of the PI3K complex, obscurin-PH blunts the pro-survival and metastatic signaling of the PI3K/AKT/NF-κB axis. In preclinical models of triple-negative breast cancer (TNBC), obscurin-PH has demonstrated the ability to inhibit cell migration, invasion, and growth. Furthermore, it serves as a chemo-sensitizer that synergizes with doxorubicin, potentially allowing for the use of lower, less cardiotoxic doses of chemotherapy while maintaining therapeutic efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on obscurin-PH.